scholarly journals Mental Symptoms and Drug Use in Maintenance Treatment with Slow-Release Oral Morphine Compared to Methadone: Results of a Randomized Crossover Study

2014 ◽  
Vol 21 (2) ◽  
pp. 97-104 ◽  
Author(s):  
Uwe Verthein ◽  
Thilo Beck ◽  
Christian Haasen ◽  
Jens Reimer
Keyword(s):  
Alcohol Use ◽  
Drug Use ◽  
Treatment Satisfaction ◽  
Maintenance Treatment ◽  
Slow Release ◽  
Oral Morphine ◽  
Open Label ◽  
Positive Effects ◽  
Patient Reported ◽  
Mental Symptoms

Background: Opioid maintenance treatment is the option of choice to stabilize opioid-dependent patients. Whilst efficacy of methadone and buprenorphine has been studied extensively, fewer data on slow-release oral morphine are available. Aims: This study analyzes the effects of slow-release oral morphine compared to methadone with regard to self-reported mental symptoms, drug use and satisfaction with treatment. Methods: The study was carried out as an open-label randomized crossover trial in 14 treatment sites in Switzerland and Germany. It comprised 2 crossover periods of 11 weeks each. For measuring mental symptoms, the Symptom Checklist-27 (SCL-27) was used. Drug and alcohol use was assessed by the number of consumption days, and treatment satisfaction by a visual analogue scale. Results: A total of 157 patients were included for the analyses (per-protocol sample). Statistically significantly better outcomes for morphine as compared to methadone treatment were found for overall severity of mental symptoms (SCL-27 Global Severity Index), as well as 5 of the 6 syndrome groups of the SCL-27, and for treatment satisfaction. There were no statistically significant differences with regard to drug or alcohol use between groups. Conclusions: This study supports positive effects of slow-release oral morphine compared to methadone on patient-reported outcomes such as mental symptoms and treatment satisfaction with comparable effects on concomitant drug use. Slow-release oral morphine represents a meaningful alternative to methadone for treatment of opioid dependence.

scholarly journals Maintenance treatment for opioid dependence with slow‐release oral morphine: a randomized cross‐over, non‐inferiority study versus methadone

Addiction ◽  
2014 ◽  
Vol 109 (4) ◽  
pp. 617-626 ◽  
Author(s):  
Thilo Beck ◽  
Christian Haasen ◽  
Uwe Verthein ◽  
Stephan Walcher ◽  
Christoph Schuler ◽  
...  
Keyword(s):  
Opioid Dependence ◽  
Maintenance Treatment ◽  
Slow Release ◽  
Oral Morphine

scholarly journals Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study

2018 ◽  
Vol 53 ◽  
pp. 58-65 ◽  
Author(s):  
Francesco Pietrini ◽  
Giulio D’Anna ◽  
Lorenzo Tatini ◽  
Gabriela Alina Talamba ◽  
Costanza Andrisano ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Maintenance Treatment ◽  
Subjective Experience ◽  
Open Label ◽  
Sf 36 ◽  
Patient Reported ◽  
Long Acting ◽  
Prospective Longitudinal

AbstractBackground:To present real-world evidence on the effects of switching from oral to long-acting injectable (LAI) antipsychotic maintenance treatment (AMT) in a sample of clinically stable patients with schizophrenia, with regard to subjective experience of treatment, attitude towards drug and quality of life.Methods:50 clinically stable adult schizophrenic outpatients were recruited. At the time of enrolment (T0), all patients were under a stabilized therapy with a single oral second-generation antipsychotic (SGA) and were switched to the equivalent maintenance regimen with the long-acting formulation of the same antipsychotic. 43 patients completed the 24-month prospective, longitudinal, open-label, observational study. Participants were assessed at baseline (T0), after 12 (T1) and 24 months (T2), using psychometric scales (PANSS, YMRS and MDRS) and patient-reported outcome measures (SWN-K, DAI-10 and SF-36).Results:The switch to LAI-AMT was associated with a significant clinical improvement at T1 and T2 compared to baseline (T0). All of the psychometric indexes, as well as patients’ subjective experience of treatment (SWN-K), and quality of life (SF-36) showed a significant improvement after one year of LAI-AMT, with stable results after two years. Patients’ attitude towards drug (DAI-10) increased throughout the follow-up period, with a further improvement during the second year.Conclusions:The switch to LAI-AMT may help to address the subjective core of an optimal recovery in stabilized schizophrenic patients. A sustained improvement in patients’ attitude towards drug may help to achieve patient’s compliance. The size of this study needs to be expanded to produce more solid and generalizable results.

scholarly journals Slow-release oral morphine for opioid maintenance treatment: a systematic review

2011 ◽  
Vol 71 (6) ◽  
pp. 832-843 ◽  
Author(s):  
Jeremie Jegu ◽  
Adeline Gallini ◽  
Pauline Soler ◽  
Jean-Louis Montastruc ◽  
Maryse Lapeyre-Mestre
Keyword(s):  
Systematic Review ◽  
Maintenance Treatment ◽  
Slow Release ◽  
Oral Morphine ◽  
Opioid Maintenance Treatment

THUR 172 Phase iv study of cladribine tablets and quality of life: clarify-ms

2018 ◽  
Vol 89 (10) ◽  
pp. A22.2-A22 ◽  
Author(s):  
S Schippling ◽  
D Langdon ◽  
A Solari ◽  
B Brochet ◽  
R Hupperts ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Treatment Satisfaction ◽  
Depression Scale ◽  
Size Estimation ◽  
Open Label ◽  
T2 Lesions ◽  
Patient Reported ◽  
Phase Iv

Authors Disclaimer: http://medpub-poster.merckgroup.com/ABN2018DISC_CLARIFY.pdfBackgroundRelapsing multiple sclerosis (RMS) negatively affects health-related quality of life (HRQoL).ObjectiveAn open-label, single-arm, exploratory Phase IV study in centres in Europe and Australia will assess HRQoL in RMS patients receiving CT 3.5 mg/kg (CT3.5).MethodsEligible patients will receive CT 3.5 (cumulative) over 2 years. HRQoL (Multiple Sclerosis Quality of Life-54 [MSQoL-54]) and other patient-reported outcomes (Fatigue Severity Scale; Hospital Anxiety and Depression Scale; Treatment Satisfaction Questionnaire for Medication v1.4) will be assessed at baseline, and at 6, 12, 24 months.Other outcomes include AEs, MRI measures (T1 Gd+ lesions, T2 lesions, brain atrophy), number of relapses, and disability/functioning measures (EDSS; 9-Hole Peg Test; Timed 25-Foot Walk and Brief International Cognitive Assessment for Multiple Sclerosis). The sample size estimation is based on the power to detect a mean difference of 5 points in MSQoL-54 composite score at 24 months vs baseline.ResultsThe study aims to recruit 356 adults with RMS by 2019. Final data are anticipated in 2022.ConclusionsThis study will explore the effects of CT on HRQoL outcomes, and describe the effects of CT on treatment satisfaction and disability/functioning.Disclosure statementThe trial is sponsored by Merck KGaA, Darmstadt, Germany.

Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis

2013 ◽  
Vol 110 (10) ◽  
pp. 732-741 ◽  
Author(s):  
Luke Bamber ◽  
Maria Y. Wang ◽  
Martin H. Prins ◽  
Cathleen Ciniglio ◽  
Rupert Bauersachs ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Effect Size ◽  
Treatment Satisfaction ◽  
Study Groups ◽  
Fixed Dose ◽  
Open Label ◽  
Randomised Study ◽  
Vein Thrombosis ◽  
Patient Reported ◽  
Deep Vein

SummaryRivaroxaban, an oral, direct factor Xa inhibitor, has been approved for the treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE as a fixed-dose, single-drug regimen that does not require initial heparinisation, routine coagulation monitoring or dose adjustment. This study evaluated patient-reported treatment satisfaction in EINSTEIN DVT - a large, open-label, randomised study that compared rivaroxaban with enoxaparin/ vitamin K antagonist (VKA) therapy in patients with acute symptomatic DVT without PE. As part of EINSTEIN DVT, a total of 1,472 patients in seven countries were asked to complete a new, validated measure of treatment satisfaction - the Anti-Clot Treatment Scale (ACTS) - at scheduled visits throughout 12 months of treatment. ACTS scores were compared between study groups in the intentionto- treat population. Patients reported greater satisfaction in the rivaroxaban group compared with the enoxaparin/VKA group, with higher mean ACTS scores across visits. Mean ACTS Burdens scores were 55.2 vs 52.6 (p<0.0001) in favour of rivaroxaban, equivalent to a moderate effect size of 0.42. The treatment effect was consistent over time, with the mean score difference ranging from 2.18 (month 2) to 3.18 (month 12). Overall mean ACTS Benefits scores were 11.7 vs 11.5 in favour of rivaroxaban (p=0.006). This was associated with a small overall effect size of 0.12. The improvement in ACTS Benefits for rivaroxaban became apparent at month 2 and subsequent visits. Rivaroxaban results in improved treatment satisfaction compared with enoxaparin/VKA among patients with DVT, particularly in reducing patient-reported anticoagulation burden.

scholarly journals EFFECTS OF HAZARDOUS ALCOHOL AND DRUG USE ON ANTIRETROVIRAL ADHERENCE AND HIV VIRAL SUPPRESSION: A MEDIATION ANALYSIS

2021 ◽  
Author(s):  
Tesfaye s MOGES ◽  
Edward R CACHAY ◽  
Huifang QIN ◽  
Laura BAMFORD ◽  
David J GRELOTTI ◽  
...  
Keyword(s):  
Alcohol Use ◽  
Drug Use ◽  
Viral Suppression ◽  
Bivariate Analysis ◽  
Opioid Use ◽  
Mediation Effects ◽  
Patient Reported ◽  
Hazardous Alcohol ◽  
Hiv Viral Suppression ◽  
Amphetamine Use

Abstract Background: Little is known regarding the degree to which substance and alcohol use effects on HIV viral suppression are mediated through medication adherence. We hypothesized that the total effects of such use are mediated through adherence. Methods: We included patients with HIV (PWH) receiving care at an urban academic HIV clinic between 2014 and 2018. Eligible patients were those prescribed antiretroviral therapy who completed both patient reported outcome (PRO) questionnaires, and had subsequent plasma viral load (pVL) measurements. Measures included assessments of alcohol use (AUDIT-C), drug use (ASSIST), and self-reported adherence. Substances found in bivariate analysis to predict detectable pVL were modeled separately for mediation effects through adherence. We report natural direct (NDE) and indirect effect (NIE), marginal total effect (MTE) and percentage mediated. Results: Among 3125 Patients who met eligibility criteria, percentages of current use by category were: hazardous alcohol 25.8%, cannabis 27.1%, amphetamines 13.1%, inhalants 11.9%, cocaine 5.3%, sedative-hypnotics 4.5%, opioids 2.9%, and hallucinogens 2.3%. Excellent adherence was reported in 58% and 10% had detectable pVL. Except for sedatives use of other ascertained substances was significantly associated with worse adherence. Bivariate predictors of detectable pVL were [OR(95% CI)]: amphetamine use 2.4 (1.8 -3.2 ) and opioid use 2.3 (1.3 - 4.0) . The percentage mediated by adherence was 36% for amphetamine use, 26.5% for opioid use, and 39% for multiple substance use. Conclusion: Use of amphetamines, opioids, and multiple substances predicted detectable pVL. However, less than 40% of effects were mediated by self-reported adherence.

Sign in / Sign up

Export Citation Format

Share Document